Physician
California Cancer Associates for Research and Excellence INC
California Cancer Associates for Research and Excellence INC was paid $7.49M by Medicaid between Jan 2018 and Dec 2024, across 149 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 12% of everything it billed.
33Billing provider infoCALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
FRESNO, CA 93720
FRESNO, CA 93720
33aNPI1083661607assigned 05/28/2006
33bProvider typeUrology Physician
28Total paid$7.49M
24GClaims718,910
24DCodes billed149
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urology Physician providers in California
Rank by total paid#1 of 171
Median peer was paid$20K
This provider vs. median370×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 66,714 | $675K | |
| 2019 | 94,341 | $1.40M | |
| 2020 | 98,659 | $1.18M | |
| 2021 | 109,695 | $1.24M | |
| 2022 | 113,675 | $848K | |
| 2023 | 125,779 | $1.26M | |
| 2024incomplete | 110,047 | $888K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 83,097 | 72,606 | $880K |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 9.8% | 15,978 | 3,588 | $733K |
| J2505 | Injection, pegfilgrastim, 6 mg | 8.2% | 1,878 | 1,413 | $616K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 6.8% | 8,269 | 6,321 | $509K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 6.6% | 3,870 | 3,557 | $498K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 5.0% | 26,512 | 18,263 | $374K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 4.7% | 4,611 | 3,956 | $352K |
| J0897 | Injection, denosumab, 1 mg | 4.6% | 1,681 | 1,626 | $344K |
| J9035 | Injection, bevacizumab, 10 mg | 3.7% | 394 | 231 | $279K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.2% | 30,440 | 28,370 | $243K |
| 96367 | 3.0% | 21,003 | 13,999 | $226K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.7% | 50,302 | 38,961 | $201K |
137 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 2.2% | 14,663 | $168K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 96,247 | $150K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 2.0% | 3,943 | $147K |
| 77014 | 1.9% | 7,837 | $140K | |
| G6002 | Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | 1.6% | 7,772 | $122K |
| J9022 | Injection, atezolizumab, 10 mg | 1.6% | 135 | $121K |
| 77301 | 1.6% | 297 | $116K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 17,357 | $109K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1.3% | 418 | $98K |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | 1.0% | 202 | $78K |
| 80053 | Comprehensive metabolic panel | <1% | 62,325 | $70K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,240 | $66K |
| 99205 | Prolong outpt/office vis | <1% | 4,208 | $51K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 217 | $48K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 1,295 | $41K |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | <1% | 169 | $35K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,726 | $33K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 44 | $32K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,646 | $31K |
| 77427 | <1% | 2,168 | $28K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,177 | $27K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,386 | $26K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 48 | $25K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 4,691 | $24K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 84 | $24K |
| 96417 | <1% | 5,873 | $22K | |
| 82728 | <1% | 25,154 | $22K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,476 | $21K |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | <1% | 497 | $19K |
| 51798 | <1% | 453 | $17K | |
| 77336 | <1% | 2,467 | $17K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,019 | $15K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 14,503 | $14K |
| 83550 | <1% | 26,016 | $14K | |
| 77334 | <1% | 735 | $13K | |
| 83540 | <1% | 26,053 | $12K | |
| 96377 | <1% | 1,033 | $12K | |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | <1% | 79 | $11K |
| 96415 | <1% | 3,091 | $10K | |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 849 | $10K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 644 | $9K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,550 | $8K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 38 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 27,122 | $8K |
| 77300 | <1% | 413 | $7K | |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | <1% | 189 | $7K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,113 | $7K |
| 82378 | <1% | 5,774 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 444 | $6K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 402 | $6K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 636 | $6K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | <1% | 17 | $5K |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | <1% | 18 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,121 | $5K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,181 | $5K |
| J1437 | Injection, ferric derisomaltose, 10 mg | <1% | 35 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,989 | $5K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 18 | $4K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 655 | $4K |
| 82607 | <1% | 6,917 | $4K | |
| 82746 | <1% | 4,956 | $4K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,789 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,850 | $4K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 76 | $4K |
| 96416 | <1% | 883 | $3K | |
| 83615 | <1% | 7,188 | $3K | |
| 96523 | <1% | 278 | $3K | |
| 88185 | <1% | 135 | $3K | |
| 86300 | <1% | 2,103 | $3K | |
| 82664 | <1% | 1,513 | $3K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 25 | $2K |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | <1% | 740 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,161 | $2K |
| 99223 | Prolong inpt eval add15 m | <1% | 27 | $2K |
| 77338 | <1% | 60 | $2K | |
| 77263 | <1% | 90 | $2K | |
| 96411 | <1% | 808 | $2K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 552 | $2K |
| 77290 | <1% | 82 | $2K | |
| 81002 | <1% | 1,919 | $1K | |
| 96368 | <1% | 788 | $1K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 326 | $1K |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | <1% | 117 | $1K |
| 85045 | <1% | 3,504 | $1K | |
| 82232 | <1% | 571 | $1K | |
| 86304 | <1% | 1,011 | $841.00 | |
| 99426 | <1% | 206 | $730.37 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 15 | $672.99 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 848 | $670.72 |
| 83735 | <1% | 1,930 | $623.87 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 590 | $593.00 |
| 82784 | <1% | 1,115 | $592.21 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 215 | $515.99 |
| 77280 | <1% | 29 | $486.81 | |
| J3490 | Unclassified drugs | <1% | 4,599 | $438.27 |
| 96402 | <1% | 612 | $428.06 | |
| 90686 | <1% | 86 | $393.17 | |
| 85007 | <1% | 209 | $363.22 | |
| J9171 | Injection, docetaxel, 1 mg | <1% | 33 | $343.28 |
| 85610 | <1% | 1,404 | $327.63 | |
| 88184 | <1% | 118 | $295.26 | |
| 83010 | <1% | 303 | $279.64 | |
| 84436 | <1% | 626 | $244.04 | |
| 82105 | <1% | 406 | $168.42 | |
| 98967 | <1% | 19 | $141.11 | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 15 | $125.62 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 509 | $115.28 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 876 | $114.27 |
| 84439 | <1% | 137 | $105.97 | |
| 99490 | Ccm add 20min | <1% | 40 | $103.95 |
| 84481 | <1% | 67 | $88.40 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 312 | $76.27 |
| 82977 | <1% | 109 | $72.07 | |
| 90688 | <1% | 88 | $66.90 | |
| 85730 | <1% | 158 | $62.87 | |
| 85651 | <1% | 314 | $56.53 | |
| 84550 | <1% | 275 | $54.14 | |
| 99459 | <1% | 43 | $45.63 | |
| 84153 | <1% | 71 | $44.13 | |
| 86301 | <1% | 66 | $33.28 | |
| 77332 | <1% | 12 | $32.23 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 212 | $28.47 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 40 | $23.83 |
| 84100 | <1% | 140 | $11.79 | |
| 90756 | <1% | 165 | $7.00 | |
| 85652 | <1% | 65 | $2.41 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 76 | $0.98 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 0% | 31 | $0.00 |
| 90662 | 0% | 26 | $0.00 | |
| 99443 | 0% | 17 | $0.00 | |
| J2997 | Injection, alteplase recombinant, 1 mg | 0% | 81 | $0.00 |
| J3590 | Unclassified biologics | 0% | 13 | $0.00 |
| 80050 | General health panel | 0% | 14 | $0.00 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 27 | $0.00 |
| 36591 | 0% | 30 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 31 | $0.00 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMONSON, JEDIDIAH (OWNER)